Integer Stock Down 38%, but One Fund Just Bet $40 Million on a Turnaround

2 hours ago 2

Jonathan Ponciano, The Motley Fool

Sun, February 22, 2026 astatine 2:56 PM CST 3 min read

On February 17, 2026, Newtyn Management disclosed a caller presumption successful Integer Holdings (NYSE:ITGR), acquiring 550,000 shares worthy an estimated $43.14 million.

According to an SEC filing dated February 17, 2026, Newtyn Management initiated a caller involvement successful Integer Holdings (NYSE:ITGR), purchasing 550,000 shares. The estimated transaction worth was $43.14 million.

This was a caller presumption for Newtyn Management, accounting for 4.53% of its 13F reportable assets nether absorption arsenic of December 31, 2025.
Top 5 holdings aft the filing:
- NYSE: AD: $91.15 cardinal (9.7% of AUM)
- NASDAQ: INDV: $90.94 cardinal (9.7% of AUM)
- NASDAQ: QDEL: $86.10 cardinal (9.1% of AUM)
- NYSE: NVRI: $82.42 cardinal (8.8% of AUM)
- NASDAQ: TBPH: $80.45 cardinal (8.5% of AUM)
As of February 17, 2026, shares of Integer Holdings were priced astatine $87.66, down 37.9% implicit the past year, underperforming the S&P 500 by 49.75 percent points.

Metric

Value

Market capitalization	$3.07 billion
Revenue (TTM)	$1.83 billion
Net income (TTM)	$86.90 million
Price (as of marketplace adjacent 2/17/26)	$87.66

Integer Holdings produces a wide portfolio of aesculapian instrumentality components and finished devices, including cardiac bushed absorption systems, neuromodulation products, vascular and orthopedic instruments, and customized artillery solutions.
The steadfast operates arsenic an outsourced manufacturer, generating gross by designing, developing, and manufacturing devices and sub-assemblies for large archetypal instrumentality manufacturers (OEMs) successful the healthcare sector.
It serves multinational OEMs and their subsidiaries successful the cardiac, neuromodulation, orthopedics, vascular, and precocious surgical instrumentality markets worldwide.

Integer Holdings is simply a starring planetary aesculapian instrumentality outsource shaper with operations crossed the United States and internationally.

Medical instrumentality manufacturing is seldom flashy. It is steady, capital-intensive, and profoundly embedded successful customers’ proviso chains, and that’s portion of wherefore a caller 4.5% presumption successful a sanction down astir 38% implicit the past twelvemonth mightiness merit immoderate attention.

Integer conscionable delivered 8% full-year income maturation to $1.85 cardinal and 21% adjusted EPS maturation to $6.40. Adjusted EBITDA reached $402 million, up 12% twelvemonth implicit year, and the institution besides generated $196 cardinal successful operating currency travel for 2025.

Debt remains meaningful astatine astir $1.19 cardinal net, oregon astir 3.0 times adjusted EBITDA, but absorption is guiding to leverage betwixt 2.5 and 3.5 times successful 2026. Sales guidance for 2026 implies level to somewhat down GAAP revenue, but adjusted net are expected to clasp up.

Compared with biotech-heavy apical holdings, this is simply a antithetic benignant of risk. It is little binary and much operational. Long-term investors should absorption connected integrated growth, borderline expansion, and deleveraging. If execution holds, a beaten-down CDMO with durable lawsuit relationships tin compound quietly.

Read Entire Article